ASRT · Assertio Holdings, Inc.

Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it has received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with all applicable listing requirements. As of January 12, 2026, Nasdaq has determined that Assertio has regained compliance with the Minimum Bid Price Rule, which requires the Company’s common stock maintains a minimum bid price of $1.00 per share for a minimum of ten consecutive days, and that the matter is now closed. Mark Reisenauer, Chief Executive Officer of Assertio: “We are pleased to have regained compliance with applicable listing requirements. Importantly, we accomplished this efficiently with the successful completion of our December 2025 reverse stock-split, while preserving capital allocation flexibility.” About Assertio Assertio is a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients’ needs.

Peer-reviewed publication in “The Oncologist” is now available online Investigational same-day dosing of Rolvedon demonstrated a clinical response and adverse event profile similar to next-day dosing Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that results of a clinical trial investigating a novel dosing schedule of Rolvedon ® (eflapegrastim-xnst) injection have been peer reviewed and published in The Oncologist. In the study of patients with early-stage breast cancer (ESBC), Rolvedon, when administered on the same day (same-day dosing) as TC chemotherapy (Taxotere (docetaxel) and cyclophosphamide) demonstrated an effective neutrophil recovery and an adverse event profile similar to that seen with next-day dosing. Howard Franklin, M.D., Senior Vice President of Medical with Assertio: “We were encouraged to see that same-day dosing of Rolvedon demonstrated efficacy and safety similar to dosing one day after chemotherapy. Assertio is proud to